placebo and cAUCB (n=58/group). In order to determine whether changes in EET production underlie the effects observed, the renal expression of sPLA2, sEH and CYP450 enzymes was determined. doubled in 5/6 Nx-mice as compared to sham mice receiving placebo. Renal sEH expression was attenuated in 5/6-Nx mice but cAUCB BMS-193885 in these animals still further increased the EET-level. cAUCB also increased 5-HETE and 15-HETE, which derive from peroxidation or lipoxygenases. Similar to cAUCB, CYP450 inhibition increased HETEs and promoted albuminuria. Thus, sEH-inhibition failed to elicit protective effects in the 5/6-Nx model and showed a tendency to aggravate the BMS-193885 disease. These effects might be consequence of a shift of arachidonic acid metabolism into the lipoxygenase pathway. == Introduction == Epoxyeicosatrienoic acids (EETs) are anti-inflammatory derivatives of arachidonic acid (AA) which are generated by cytochrome P450 (CYP) epoxygenases[1]. EETs are antihypertensive, anti-inflammatory, anti-proliferative and pro-fibrinolytic. They act as an endothelium-derived hyperpolarizing factor (EDHF) in some vascular beds[1]. The CYP450 expression in the kidney is high and EETs promote renal sodium excretion[1],[2]. EET levels are dependent on the activity and expression of the CYP epoxygenases, which generate them and the enzyme soluble epoxide hydrolase (sEH) which converts the EETs to their corresponding dihydroxyeicosatrienoic acids (DHETs)[3]. DHETs subsequently leave the cell, can be conjugated in the liver and be excreted by liver or kidney[2],[4]. The activity of the sEH is therefore thought to be a major determinant of EET bioavailability[4]. Genetic deletion of the sEH as well as pharmacological inhibition increase plasma EET levels and potentiate their effects[5], and thus sEH inhibition elicits anti-hypertensive and anti-inflammatory effects[2],[5],[6]. Indeed, we have previously shown that sEH inhibition reduces angiotensin II-induced hypertension[7], neo-intima formation in hyperlipidemic mice[8]and vascular remodelling in the monocrotaline-model in rats[9]. Hypertension and inflammation are important progression factors for renal disease and thus it is logical to assume that sEH inhibition is a strategy to prevent progression of renal diseases[2],[5]. Indeed, it has been demonstrated that sEH inhibition improves renal vascular function, decreased glomerular injury and renal inflammation in rat models of angiotensin-induced and DOCA-salt hypertension[10][12]. A main limitation of these models is however that their high inflammatory activity does not necessarily reflect the situation of chronic renal disease in man which is dominated by sclerotic and fibrotic processes and which is characterized by a progressive, self-perpetuating nature[13],[14]. BMS-193885 In animal experiments such a situation can be modelled by 5/6-nephrectomy (5/6-Nx). In this remnant kidney model, the substantial reduction in renal mass leads to compensatory renal hypertrophy, glomerula hyperfiltration and subsequently progressive chronic renal failure as consequence of glomerulo-sclerosis and interstitial fibrosis[15][17]. Although also in the remnant kidney model, the renin-angiotensin-system is involved in disease progression[18], it is only one of several factors contributing to a complex disease scenario. Given the similarities between the remnant kidney model in rodents and the pathophysiology of progressive chronic renal failure in humans, we postulated that sEH inhibitors could be of therapeutic value. We tested this hypothesis in the rodent remnant kidney model. Unexpectedly and in contrast to previous data from inflammation driven renal failure models we observed that sEH inhibition had a tendency to accelerate the disease process in this model. == Methods == == Animal preparations == SV129 which were purchased from Charles Rivers Laboratories (Sulzfeld, Germany) were used for this study, as other strains do not develop progressive renal failure mice[19]. Animals were housed in cages at constant temperature (22C) and humidity (50%) and were exposed to a 12-hour dark/light cycle. Food and water were supplied ad libitum. The experiments were performed in accordance with the National Institutes of Health Guidelines on the Use of Laboratory Animals. Both, the University Animal Care Committee and the Federal Authorities for Animal Research of the Regierungsprsidium Darmstadt (Hessen, Germany) approved the study protocol (approval number V54-19c20/15-F28/05 and -F61/16). After 7 days of adaptation, the animals BMS-193885 were randomly allocated to 5/6 nephrectomy (5/6-Nx) or sham operation. The surgery was performed under Isoflurane anaesthesia as Mouse monoclonal to HSV Tag previous BMS-193885 described by others with modifications[19]. In brief: A left dorsal longitudinal incision was performed to expose the left kidney. The upper branch of the left renal artery was ligated by 60 prolene suture to produce about one third area with visible renal ischemia infarct; the lower pole of the left kidney (about one third kidney size) was removed by cautery. After 7 days of recovery, the right kidney was exposed.